NCT02613520 - Safety and Immunogenicity in Age De-Escalation of PfSPZ Vaccine in Tanzanian Adults, Children, and Infants | Biotech Hunter

Enrollment

105

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

February 28, 2017

Study Completion Date

March 31, 2017

Conditions

Malaria

Interventions

BIOLOGICAL

PfSPZ Vaccine

Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)

OTHER

Normal Saline

0.9% Sodium chloride

BIOLOGICAL

PfSPZ Challenge (for CHMI)

live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge

Trial Locations (1)

Unknown

Bagamoyo Research and Training center of the Ifakara Health Institute, Bagamoyo